Lilly Eli & Co Stock Price, News & Analysis

Eli Lilly (NYSE: LLY) will report its fourth-quarter 2025 financial results on February 4, 2026. A conference call with the investment community and media will be held the same day beginning at 10 a.m. Eastern. Investors, media and the public can access a live webcast via the company's investor website, and a replay will be posted after the call.

Eli Lilly (NYSE: LLY) announced that the U.S. FDA granted Breakthrough Therapy designation to sofetabart mipitecan (LY4170156) on January 20, 2026 for adult patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received prior bevacizumab and mirvetuximab soravtansine, if eligible.

Sofetabart mipitecan is an FRα antibody-drug conjugate using proprietary linker technology and an exatecan payload. The designation was based on encouraging preliminary Phase 1a/b results showing responses across all FRα expression levels, activity in patients who progressed after mirvetuximab soravtansine, and a tolerability profile with low rates of interstitial lung disease, peripheral neuropathy, and alopecia. Lilly has initiated the global Phase 3 FRAmework-01 trial (NCT07213804).

Summary not available.

Vida Ventures applauded Aktis Oncology (Nasdaq: AKTS) on entering the public markets after an IPO that raised $318 million. Vida said it co-led Aktis’ Series A, remained a long‑term investor and was the company’s second‑largest shareholder pre‑IPO, with Helen Kim serving on the Aktis board since 2021. Vida co‑founder Brian Goodman served as Aktis’ founding COO and later CBO. Vida highlighted Aktis’ pipeline led by AKY-1189 (actinium-225, Nectin-4) and AKY-2519 (B7-H3), prior private funding of approximately $346 million, and a strategic collaboration with Eli Lilly that Vida described as a deal valued up to $1.2 billion.

Eli Lilly (NYSE: LLY) reported topline 36-week results from the open-label Phase 3b TOGETHER-PsA trial evaluating concomitant Taltz (ixekizumab) and Zepbound (tirzepatide) versus Taltz alone in adults with active psoriatic arthritis and obesity/overweight with ≥1 weight-related condition. The study met its primary endpoint: 31.7% on combination therapy achieved ACR50 plus ≥10% weight loss vs 0.8% on Taltz alone (p<.001). A key secondary showed ACR50 rates of 33.5% vs 20.4% (64% relative increase, p<.05). Safety was consistent with known profiles; common adverse events with the combination included nausea, diarrhea, constipation, and injection site reactions. Detailed 36-week data will be presented and reviewed with regulators.

Lilly (NYSE: LLY) agreed to acquire clinical-stage Ventyx Biosciences for $14.00 per share in an all-cash deal valued at approximately $1.2 billion. The acquisition adds Ventyx's small-molecule pipeline, including class-leading NLRP3 inhibitors aimed at oral treatments for inflammatory-mediated diseases across cardiometabolic, neurodegenerative and inflammatory disorders. The deal carries an approximate 62% premium to Ventyx's 30-day VWAP through Jan. 5, 2026, is not subject to financing, and is expected to close in the first half of 2026 pending shareholder and regulatory approvals.

Eli Lilly (NYSE: LLY) reported topline Phase 3 ATTAIN-MAINTAIN results showing oral orforglipron met the primary and all key secondary endpoints for 52-week weight maintenance versus placebo after prior treatment with Wegovy or Zepbound.

Key figures: participants switching from Wegovy retained their weight loss with an average difference of 0.9 kg; those switching from Zepbound showed an average difference of 5.0 kg at 52 weeks. Safety was consistent with prior studies; GI events were most common. Lilly has submitted an NDA to the FDA and received a Commissioner’s National Priority Voucher.

Eli Lilly and Company (NYSE: LLY) will participate in the 44th Annual J.P. Morgan Healthcare Conference, scheduled for Jan. 12-15, 2025. David A. Ricks, Lilly chair and CEO, will appear in a fireside chat on Tuesday, Jan. 13 at 5:15 p.m. ET.

A live audio webcast will be accessible via the company's Webcasts & Presentations investor page and a replay will be available on the same site for approximately 90 days.

Eli Lilly (NYSE: LLY) reported updated Phase 3 EMBER-3 results for Inluriyo (imlunestrant) in ER+, HER2– advanced breast cancer on Dec 12, 2025.

Key efficacy highlights: as monotherapy in ESR1‑mutated patients, imlunestrant reduced risk of progression or death by 38% (median PFS 5.5 vs 3.8 months; HR=0.62) and showed an 11.4‑month median OS improvement (34.5 vs 23.1 months; HR=0.60) (boundary for significance not met). The imlunestrant + abemaciclib combination achieved median PFS 10.9 months (HR=0.59), a favorable OS trend (HR=0.82), and extended time to chemotherapy by >1 year (27.8 vs 15.5 months). Safety remained consistent with prior reports; OS follow‑up is ongoing.